HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Isradipine in patients with acute ischaemic cerebral infarction. An overview of the ASCLEPIOS Programme.

Abstract
Calcium-related mechanisms are an integral part of metabolic reactions during acute cerebral infarction. In an animal model of stroke, the calcium antagonist isradipine was shown to protect neurons against ischaemia. In order to improve the neurological and functional outcome of human stroke patients, a randomised, double-blind, placebo-controlled multicentre study was started in up to 600 patients with acute ischaemic brain infarction. Since early treatment is considered to be of great importance, patients must be recruited no more than 12 hours after stroke onset. Medical, ECG, laboratory, neurological and functional evaluations are conducted for up to 90 days after stroke.
AuthorsA Azcona, X Lataste
JournalDrugs (Drugs) Vol. 40 Suppl 2 Pg. 52-7 ( 1990) ISSN: 0012-6667 [Print] New Zealand
PMID2150642 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Calcium Channel Blockers
  • Pyridines
  • Isradipine
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Brain Ischemia (drug therapy)
  • Calcium Channel Blockers (therapeutic use)
  • Cerebral Infarction (drug therapy)
  • Double-Blind Method
  • Female
  • Humans
  • Isradipine
  • Male
  • Middle Aged
  • Pyridines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: